|Positive WB detected in||Daudi cells, Raji cells|
|Positive IF detected in||rat brain tissue|
|Positive FC detected in||Raji cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunofluorescence (IF)||IF : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
13395-1-AP targets CD86 in WB, IHC, IF, FC, ELISA applications and shows reactivity with human, rat samples.
|Tested Reactivity||human, rat|
|Cited Reactivity||human, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||CD86 fusion protein Ag4063|
|Full Name||CD86 molecule|
|Calculated molecular weight||329 aa, 38 kDa|
|Observed molecular weight||65-70 kDa|
|GenBank accession number||BC040261|
|Gene ID (NCBI)||942|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
CD86 (also known as B7.2) is a costimulatory molecule belonging to the immunoglobulin superfamily. Primarily expressed on antigen-presenting cells (APCs), including B cells, dendritic cells, and macrophages, CD86 is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of CD86 with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of CD86 with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. This antibody detects a band of approximately 65-70 kDa, consistent with glycosylated form of CD86 (PMID: 8592066, 21849678).
Neuropsychiatr Dis Treat
Soluble epoxide hydrolase inhibition enhances anti-inflammatory and antioxidative processes, modulates microglia polarization, and promotes recovery after ischemic stroke.
A Comparison of Splenic Pathologic Change and Immune Function in HBV-Related Portal Hypertension and Chinese Budd-Chiari Syndrome Patients with Hypersplenism.
KDM3A inhibition modulates macrophage polarization to aggravate post-MI injuries and accelerates adverse ventricular remodeling via an IRF4 signaling pathway.
Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage.
Front Cell Neurosci
Electroacupuncture Pretreatment Alleviates Cerebral Ischemic Injury Through α7 Nicotinic Acetylcholine Receptor-Mediated Phenotypic Conversion of Microglia.